CHICAGO--(BUSINESS WIRE)--NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present data on cardiac function in patients treated with aldoxorubicin in combination with Doxorubicin during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.
“Our data will be beneficial for the larger scientific community as we continue our research to understand potential cancer treatments,” said Patrick Soon-Shiong, MD, founder of NantWorks. “We look forward to sharing our data at ASCO and further research endeavors.”
Presentation Details
Lack
of cardiac toxicity in patients treated with Aldoxrubicin with
Doxorubicin equivalent doses beyond 1000mg/m2, Abstract
#11585
WHO: NantOmics, LLC
WHAT: Sarcoma
Session
WHEN: June 2, 8:00-11:30 AM CST
WHERE:
Hall A, McCormick Place
Presentation Summary
A
total of 52 patients were enrolled in three phases of the study and
results found that in 11 patients, the median cumulative doxorubicin
dose prior to aldoxorubicin treatment was 158 mg/m2. The cumulative
aldoxorubicin dose ranged from 1000 to 7500 mg/m2. As a result, no
patient developed any sign or symptom of clinical congestive heart
failure. Ventricular ejection fractions ranged from 45-74% baseline, and
50-77% at end of treatment, median being 60% both at the beginning and
end of treatment. The study shows that aldoxorubicin lacks
cardiotoxicity in patients treated with aldoxorubicin alone or in
combination with ifosfamide/mesna. No evidence of cardiac toxicity of
aldoxorubicin up to doxorubicin equivalent dose of 7500mg/m2.
About NantOmics
NantOmics, a member of the NantWorks
ecosystem of companies, delivers molecular analysis capabilities with
the intent of providing actionable intelligence and molecularly driven
decision support for cancer patients and their providers at the point of
care. NantOmics is the first molecular analysis company to pioneer an
integrated approach to unearthing the genomic and proteomic variances
that initiate and drive cancer, by analyzing both normal and tumor cells
from the same patient and following identified variances through from
DNA to RNA to protein to drug. NantOmics has a highly scalable
cloud-based infrastructure capable of storing and processing thousands
of genomes a day, computing genomic variances in near real-time, and
correlating proteomic pathway analysis with quantitative multi-plexed
protein expression analysis from the same micro-dissected tumor sample
used for genomic analysis. For more information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
